Celebrations may be in order for Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The consensus estimated revenue numbers rose, with their view now clearly much more bullish on the company's business prospects.

After the upgrade, the four analysts covering Kiniksa Pharmaceuticals are now predicting revenues of US$169m in 2022. If met, this would reflect a substantial 139% improvement in sales compared to the last 12 months. Before the latest update, the analysts were foreseeing US$134m of revenue in 2022. It looks like there's been a clear increase in optimism around Kiniksa Pharmaceuticals, given the sizeable gain to revenue forecasts.

Check out our latest analysis for Kiniksa Pharmaceuticals

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. It's clear from the latest estimates that Kiniksa Pharmaceuticals' rate of growth is expected to accelerate meaningfully, with the forecast 5x annualised revenue growth to the end of 2022 noticeably faster than its historical growth of 160% p.a. over the past three years. Compare this with other companies in the same industry, which are forecast to grow their revenue 14% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Kiniksa Pharmaceuticals is expected to grow much faster than its industry.

The Bottom Line

The highlight for us was that analysts increased their revenue forecasts for Kiniksa Pharmaceuticals this year. The analysts also expect revenues to grow faster than the wider market. Seeing the dramatic upgrade to this year's forecasts, it might be time to take another look at Kiniksa Pharmaceuticals.

Unanswered questions? At least one of Kiniksa Pharmaceuticals' four analysts has provided estimates out to 2024, which can be seen for free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.